A host of new oral anticoagulant agents, which could become much-needed replacements for warfarin and be used as alternatives to heparin, are under development. Two of these agents are now in phase 3 trials. Experts are cautious, however, following the failure of the first such agent, ximelagatran, to reach the US market because of liver-toxicity issues. Researchers are optimistic that at least 1 or 2 of the new compounds will succeed and provide patients who are taking warfarin with a much more userfriendly treatment.
The 2 agents furthest in development are the factor IIa inhibitor dabigatran (Boehringer Ingelheim) and the factor Xa inhibitor rivaroxaban (Bayer HealthCare and Ortho-McNeil Pharmaceuticals Inc). Several other companies also have orally available factor Xa inhibitors in earlier clinical development, including Bristol-Myers Squibb Co, Eli Lilly and Co, Yamanouchi Pharmaceutical Co, and DuPont Pharmaceuticals Co.
Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs